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periprosthetic infection
Ralf Dieckmann1*, Dino Schulz1, Georg Gosheger1, Karsten Becker2, Kiriakos Daniilidis3, Arne Streitbürger1,
Jendrik Hardes1 and Steffen Hoell1Abstract
Background: Two-stage revision arthroplasty is today regarded as the gold standard treatment method for deep
prosthetic joint infection. The aim of the present study was to evaluate clinical and functional outcomes with the
Modular Universal Tumor And Revision System (MUTARS) RS stem in patients undergoing two-stage revisions.
Methods: The functional and clinical outcomes for 43 patients who had undergone two-stage revision procedures
for PJI were analyzed in a retrospective study. The minimum follow-up period was 24 months. Shorter follow-up
periods were only observed when there were complications such as loosening or recurrent infection. The mean
follow-up period was 3.86 years (range 7 months to 11.6 years).
Results: The success rate with infection control for PJI was 93%. Reinfection occurred in four cases (7%). The risk of
reinfection after MRSA infection was 20.5 times greater (P >0.01) than with sensitive or unknown bacteria. Two
aseptic loosening occurred after 7 and 20 months. The average Harris Hip Score was 80 (range 62–93).
Conclusion: This retrospective study showed a 93% rate of eradication using specific antibiotic therapy. With the
modular MUTARS RS stem, there was a low rate of aseptic loosening of 4.6%. MRSA infection was identified as a risk
factor for reinfection. The two-stage procedure with modular cementless implants used is therefore appropriate for
treating periprosthetic infections associated with hip endoprostheses.
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The number of total hip arthroplasties (THA) carried
out in Germany has increased in recent years up to
160,000 annually [1]. The main reasons for this are the
aging of the population and technical improvements in
orthopedic surgery. The current rate of prosthetic joint
infection (PJI) in Europe and the United States is around
0.6–1.0% for THA [1-3]. This indicates that not only the
number of THA increasing, but also the absolute num-
bers of infections.
Treatment for PJI depends on the duration of symptoms.
Early or hematogenous infections, with symptoms for less
than 4 weeks, can be treated with local debridement and* Correspondence: Ralf.Dieckmann@ukmuenster.de
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article, unless otherwise stated.retention of the implant. In patients with late infections,
one-stage or two-stage procedures are necessary [4].
As success rates are above 90%, two-stage revision is
the first choice for patients with late PJI in Germany [5,6].
Either cemented or cementless revision systems can be
used [5-9]. Cemented fixation was used for reimplantation
in the past, because it allows antibiotics to be used in the
cement to reduce the risk of recurrent infection [7,8].
However, following good results with cementless fixation
in aseptic surgery [10,11], there have been increasing
numbers of publications describing successful cementless
fixation in two-stage revision procedures [3,5,12-17].
The aim of the present study was to evaluate clinical
and functional outcomes with the Modular Universal
Tumor And Revision System (MUTARS) RS stem, which
has been used in our department for more than 10 years,
in patients undergoing two-stage revisions.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Patients
The functional and clinical outcomes for 43 patients
who had undergone two-stage revision procedures for
PJI were analyzed in a retrospective study. The patients
had been treated between 2000 and 2012 in a university
orthopedic department. We had an ethics approval of
the local ethic committee of the University of Münster
(2014-324-f-N). Every patient were informed about the
study and agreed to publish their data. A consent state-
ment was signed.
They included 21 men and 22 women, with an average
age of 66 years (range 40–84 years). The minimum
follow-up period was 24 months. Shorter follow-up pe-
riods were only observed when there were complications
such as loosening or recurrent infection. The mean
follow-up period was 3.86 years (range 7 months to
11.6 years). The indication for THA was primary osteo-
arthritis (OA) in 31 cases, femoral neck fracture in six
cases, secondary OA after acetabular fracture in four
cases, rheumatoid arthritis in one case, and necrosis of
the femoral head in one case. The last operation for the
explantation of the prosthesis was in mean 43,5 months
(1 months – 24 years).
Clinical and functional follow-up
All of the patients received radiographic and clinical
follow-up examinations. In case of death (n = 2), the last
clinical and radiographic examination was evaluated,
and inquiries were also made of the patient’s relatives.
The Della Valle–Paprosky classification was used to clas-
sify femoral bone defects [18]. The functional outcome
was evaluated at the outpatient examinations using the
Harris Hip Score [19].
End points and definitions
The inclusion criterion for the patients was a minimum
follow-up period of 24 months, or less in case of early
loosening of the stem or infection. PJI was diagnosed if
at least one diagnostic method was positive in accord-
ance with the Centers for Disease Control criteria [20].
The primary end points of the study were successful
treatment for infection or reinfection with loosening of
the prosthesis. Clinical cure, with no clinical signs of in-
flammation and negative C-reactive protein findings,
was assessed by the treating clinician at the date of the
last available follow-up. Aseptic loosening of the stem
was a secondary end point.
Surgical treatment
If at least one Centers for Disease Control criterion
[20] was positive, a two-stage revision was performed
(Figure 1). All of the patients were treated with an
antibiotic-loaded polymethylmethacrylate (PMMA) spacer.We collected at least three biopsies for microbiological
examination. The composition of the antibiotics in the
spacer was adapted to the bacterial resistance (Table 1).
Between 2000 and 2004, seven patients were treated with
a short period of parenteral antibiotic therapy for a mean
of 20 days (range 17–26 days) between both operations.
Since 2005, all patients have been treated with parenteral
antibiotic therapy for at least 2 weeks, followed by oral
antibiotic therapy for at least 4 weeks. If the bacteria in-
volved were not identified, calculated antibiosis with a
cephalosporin and clindamycin was administered. In other
cases, specific antibiotic therapy was used.
Before replantation we paused the antibiotic therapy
for at least two weeks. If the C-reactive protein was less
than 2 mg/dl we do the reimplantation. The MUTARS
RS stem (Implantcast Ltd., Buxtehude, Germany) was
used for reimplantation. It is a modular revision stem
with a hexagonal stem design [21] and has included a
hydroxyapatite layer since 2006. For acetabular recon-
struction we used in three cases a cemented dual mobil-
ity cup, in eight cases a cemented polyethylene, in 22
cases a cementless cup and in 10 cases a reconstruction
with an antiprotrusio cage. In three cases we used the
cage in combination with spongiosa chips of an allograft.
After reimplantation, 2 weeks of the parenteral antibiotic
therapy was administered, followed by 4 weeks of oral
antibiotic therapy.
Statistical analysis
Statistical analysis was performed with IBM SPSS Statistics
for Windows, version 21.0 (IBM Corporation, Armonk,
New York, USA).
Results
Diagnosis of the periprosthetic infection
The leading indication for explantation was bacteria in
the aspiration fluid in 18 cases, fistula in 12 cases, puru-
lent synovial fluid in eight cases, elevated leukocyte
counts (>4500) in the aspiration fluid in combination
with elevatd C-reactive protein in four cases, and posi-
tive leukocyte scintigraphy in combination with elevated
C-reactive protein in one case. Microorganisms were
identified in 88.3% of cases (Table 2). Staphylococcus
aureus was present in most cases.
Infection therapy
A spacer exchange and repeated complete PJI manage-
ment were necessary in four cases. The cause of persisting
infection was a nonsensitive spacer in a patient with
methicillin-resistant S. aureus (MRSA) in one case, persist-
ent fistula in two cases, and persistently high C-reactive
protein levels in one case. The mean C-reactive protein
level was 0.8 mg/dL (0.5–2.0 mg/dL) at the time of
reimplantation.
Figure 1 Two-stage procedure in a 74-year-old-woman. a: Septic loosening of the hip. b: Explantation of the hip prosthesis and spacer
implantation. c: Reimplantation of a hip prosthesis with the MUTARS RS stem and a cementless cup.
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93%. Reinfection occurred in four cases (7%) (Table 3).
Another two-stage revision with a cemented prosthesis
was carried out in two cases, and resection arthroplasty
was performed in two patients. Two patients with re-
infection had MRSA infections. The risk of reinfection
after MRSA infection was 20.5 times greater (odds ratio;
P >0.01) than with sensitive or unknown bacteria.
Della Valle–Paprosky classification of the femur and
radiographic analysis
The femoral defects were classified using the Della Valle–
Paprosky classification [18]. There were nine patients with
type II, 30 with type IIIa, and four with type IIIb femoral
defects. A MUTARS RS stem was used in all cases. In two
cases there was a subsidence of the stem of 5 mm and
3 mm. Both patients had no sign of loosening after a
follow-up of three years.Table 1 Antibiotic combinations in antibiotic-loaded
polymethylmethacrylate (PMMA) spacers





Gentamicin/clindamycin/flucloxacillin 2Comorbidities and risk factors
Comorbid conditions that were documented consisted
of obesity (body mass index >30) in 11 patients, diabetes
mellitus in eight patients, malignancy in five patients,
long-term cortisone therapy in three patients, endocardi-
tis in two patients, chronic obstructive lung disease in
two patients, osteomyelitis of the femur in one patient,
PJI of the contralateral knee endoprosthesis in one patient,
hepatitis B in one patient, hepatitis C in one patient, and
long-term methotrexate therapy in one patient. Four pa-
tients had more than one comorbidity.
The number of surgical procedures that had been
carried out before the two-stage procedure was also
documented as an additional potential risk factor. A
two-stage procedure had already been performed in
three patients; the infection occurred after the primary
operation in 18 patients; 16 patients had one aseptic
revision, five patients had two aseptic revisions, and one
patient had one septic revision with retention of the
prosthesis.
Complications unrelated to infection
Two complications associated with the stem occurred.
Both involved aseptic loosening after 7 and 20 months,
respectively, with a type IIIa Della Valle–Paprosky defect
in one case and a type IIIb defect in the other (Figure 2).
The preoperative C-reactive protein findings were nega-
tive and no bacteria were found in the intraoperative
























Patients with two species 6
Patients with eight species 1
*Two were methicillin-resistant.
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stem was carried out in both cases.
Wound healing problems occurred in four cases. Heal-
ing followed after local debridement in all of these pa-
tients. There was a trend for patients with diabetes
mellitus to have a 4.5 times (odds ratio) greater risk of
developing wound healing problems. One patient devel-
oped peroneal paralysis postoperatively; immediate revi-
sion surgery with shortening of the femoral head was
necessary. One patient had a periprosthetic fracture after a
fall; osteosynthesis was carried out successfully. AnotherTable 3 Patients with recurrent infection
Patient
no.






2 Primary coxarthrosis – Aseptic ste
3 Femoral neck fracture – –
4 Primary coxarthrosis Fistula –
MRSA, methicillin-resistant Staphylococcus aureus.patient developed dislocation of an inlay, and the cup had
to be exchanged. One patient developed recurrent disloca-
tion after reimplantation; the inlay was changed to a 10°
insert and the antetorsion of the stem was altered. An-
other patient had aseptic loosening of an antiprotrusio
cage, and an exchange was necessary (Table 4).
Functional outcome
Evaluation of the postoperative Hip Society Score was
possible in 37 cases. Aseptic or septic exchanges of the
stem had already been performed in three cases already,
two of the patients had died, and it was not possible to
contact the patient for the questionnaire in one case.
The average Harris Hip Score was 80 (range 62–93). Ex-
cellent results were seen in four cases, good results in
19, fair results in 11, and poor results in three cases.
There was no difference in the functional outcome de-
pending on the bony defect.
Discussion
Two-stage revision arthroplasty is today regarded as the
gold standard treatment method for deep prosthetic
joint infection [22,23]. However, there has been debate
on whether cemented or cementless reimplantation is
better, in view of the lack of local antibiotic protection
with the latter method [5-7,9,12-15,24-26]. In earlier
studies on cementless two-stage revision, high rates of
loosening and reinfection were reported [25,26]. How-
ever, more recent studies have described good eradica-
tion rates and good prosthetic survival [5,6,14,24]. The
present study focuses on the reinfection rate and early
loosening of the MUTARS RS stem (Implantcast Ltd.,
Buxtehude, Germany).
Limitation of this study are the retrospective nature of
the study and the relatively short follow-up period of
2 years in a few cases. However, most cases of reinfection
occur in the first few years after reimplantation [15,24]
and most studies on cementless two-stage revision have
reported follow-up periods of 2 years [5,6,12,24,25]. Sub-
sidence of the stem and early loosening of the components
would also occur within the first few years [27-30].
The eradication rates achieved ranged from 82% to 100%






hange MRSA 24 – 16.8
m exchange – 8 – 32.0
MRSA 77 – 30.0
S. epidermidis 4.7 – 22.0
Figure 2 Aseptic loosening of a MUTARS RS stem in case of a Paprosky IIIa defect. a: postoperative x-ray. b: 18 months x-ray control with
aseptic loosening. c: Revision with a cemented stem.
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[31-35]. The eradication rate observed in the present
study was 93%, including multiresistant bacteria. The
treatments administered in other studies vary widely.
Haddad et al. [6] used a course of 5 days of parenteral
antibiotics, followed by oral antibiotics for 3 weeks in the
interval up to reimplantation, with an eradication rate of
92%. Other studies have reported administering intraven-
ous antibiotics for up to 6 weeks [5,12-14,24]. Another
limitation in the present study is that we had two differ-
ent treatment protocols. Initial we treated seven patients
in mean only 20 days parenteral between both opera-
tions. We had no reinfection with this kind of treatment.Table 4 Patients with complications unrelated to the
infection
Complications Patients (n)
Wound healing problems 4
Aseptic loosening of the stem 2
Recurrent dislocations 1
Aseptic loosening of the cup 1
Periprosthetic fracture after collaps 1
Peroneal palsy 1
Inlaydislocation 1To our knowledge there is no study describing the gold
standard for the perioperative treatment [23,36]. Since
2004 we treated with a periods of 2 weeks with parenteral
antibiotic treatment and 4 weeks of oral antibiotic ther-
apy were used in the interval to reimplantation, followed
by a further course of antibiotic therapy with 2 weeks of
parenteral treatment followed by 4 weeks of oral treat-
ment after reimplantation. Fink et al. reported a 100%
eradication rate with non-multiresistant bacteria using this
sequence [5]. The 2-week period of parenteral antibiotic
therapy appears to be short, but it is consistent with the
recommendations of Zimmerli et al. [4,37]. The 3-month
period of antibiotic treatment is also in agreement with
the recommendations [4,37].
Local methods of treatment for PJI also vary widely. In
earlier studies, resection arthroplasty [25,26], antibiotic
beads [6,12], and articulating spacers [15] were used.
Gentamicin, alone or in combination with vancomycin,
was often used [6,12]. However, it was not possible to
successfully treat gram-negative bacteria in particular
with this combination. Masri et al. and Fink et al. were
the first to describe specific local antibiotic therapy
[5,24], which makes it possible to treat resistant bacteria
successfully, on the one hand, while on the other the
development of new resistance can be avoided. Specific
antibiotic therapy was therefore always used in the
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teria, gentamicin alone was used. The results, with an
eradication rate of 93%, provide support for this form of
local therapy.
Multiresistant bacteria such as methicillin-resistant S.
aureus (MRSA) are an increasing problem [38] and are
associated with higher reinfection rates [39]. Kilgus et al.
reported that the reinfection rate in cases of multiresis-
tant S. aureus and S. epidermidis has increased from
19% to 52% [40]. Lim et al. compared 24 patients with
resistant microorganisms with 13 patients with nonresis-
tant microorganisms [41] and noted a recurrence rate of
33% in the resistant group, in comparison with no fail-
ures in the nonresistant group. Similar results were ob-
served in the present study. Only two patients had
MRSA infections, but reinfection occurred in both cases.
One had already undergone a two-stage revision due to
MRSA infection. The reinfection rate was significantly
higher in patients with MRSA infection.
Aseptic loosening occurred in 4.6% of the cases. In a
review, Wirtz et al. reported mean loosening rates of
4.4% with cementless stems in cases of aseptic revision
and 21.2% with cemented stem revisions [42]. Dohmae
et al. [43] demonstrated that there is a 70% lower shear
force capacity in revision cases in comparison with pri-
mary implantations. This may be the reason why the ce-
ment does not fuse with spongy bone. It is therefore
necessary for the revision implant to bridge the bone af-
fected by the original femur implant. In two-stage revi-
sions, Nestor et al. [25] reported an 18% rate of
loosening using a nonmodular, proximally coated stem,
while other studies have reported loosening rates of 0%
using nonmodular or modular stems [5,6,12-14,17,24].
Most of the studies do not report any classification of
the defects. The loosening rates observed with two-stage
revisions are equal to or better than those with aseptic
revisions [42]. It was therefore concluded that the loos-
ening rate depends on the defects involved, rather than
on the two-stage procedure.
Other risk factors have also been identified that have
an unfavorable influence on the course of salvage proce-
dures following infection. Particularly with primary hip
arthroplasty, these factors include postoperative osteoarth-
ritis, multiple surgical revisions, cutaneous and urinary
tract infections, chronic liver disease, inadequate antibiotic
prophylaxis, and malignancies [44]. Further risk factors
include rheumatoid arthritis, steroid therapy, diabetes
mellitus, immunosuppressant therapy, and nosocomial in-
fections [45]. The only risk factor for reinfection identified
in the present data was the presence of multiresistant bac-
teria. In fact, the same risk factors appear to be present
with two-stage revisions as in primary arthroplasty. It is
possible that the number of patients included was too
small for statistical significance to be reached.Conclusions
This retrospective study showed a 93% rate of eradica-
tion using specific antibiotic therapy in accordance with
the recommendations made by Zimmerli et al. [4] and
Trampuz et al. [46]. With the modular MUTARS RS
stem, there was a low rate of aseptic loosening of 4.6%.
MRSA infection was identified as a risk factor for re-
infection. The two-stage procedure used with the modu-
lar cementless implants is therefore appropriate for
treating periprosthetic infections associated with hip
endoprostheses.
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